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Abstract: Glucocorticoids are essential in treating many disorders and they are widely used 
in spite of their negative impact on the skeletal system. As bisphosphonates reduce bone 
resorption through their action on osteoclasts, they play an important role in management of 
glucocorticoid-induced osteoporosis. Unlike other bisphosphonates, zoledronic acid is given by 
intravenous infusion and it has a potential advantage of increasing the compliance and adherence 
of patients when it is given 5 mg once a year. However, this treatment modality seems to be 
associated with more adverse events than oral administrations, and further studies with longer 
follow-up periods must be conducted to determine the safety and cost-effectiveness of long-term 
  treatment with zoledronic acid.
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Introduction
Glucocorticoids (GCs) are steroidal stress hormones which have many different 
  biological functions.1,2 Through binding to GC receptors, they exert most of their 
effects, such as regulating tissue differentiation during development, controlling 
intermediary metabolism and coordinating the adjustment of physiological processes 
in response to stress.3–5 Because of these effects, synthetic GCs have been developed 
which are widely used in the treatment of allergic, inflammatory, lymphoproliferative 
disorders, and autoimmune diseases.6–10 However, such a treatment is not without 
  shortcomings: GCs exert a negative impact on the skeletal system as they result in a 
rapid, early phase of bone loss which is followed by a more chronic and progressive 
phase due to excessive bone resorption, in which finally the bone mass declines because 
of impaired bone formation.11 The administration of GCs is the most frequent second-
ary cause of osteoporosis and it has been demonstrated that more than one third of 
individuals treated with GCs for 5 to 10 years will have an osteoporotic fracture.12,13
The purpose of this review is to discuss the pathophysiology of glucocorticoid- 
induced osteoporosis (GIO) and the efficacy and safety of zoledronic acid in the 
treatment of this disorder.
Pathophysiology of glucocorticoid-induced osteoporosis
Although it is estimated that, 30%–50% of patients using long-term GCs experience rel-
evant bone loss, the exact prevalence of GIO is still unknown.14,15 The pathophysiology 
of GIO is complicated, as GCs may exert their effects on the skeletal system in many 
ways. In the beginning GCs cause an increase in bone resorption, however the most 
important effect of GCs is their action in decreasing bone formation by decreasing Therapeutics and Clinical Risk Management 2010:6 220
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osteoblast proliferation and inhibiting osteoblasts from 
producing new bone.16,17 In addition, osteocyte apoptosis 
can be detected in GIO, which results in microarchitectural 
deterioration, as these cells are considered to determine bone 
strength independent of bone mineral density (BMD).18 On 
the other hand, GCs also have systemic effects on bone 
metabolism as they have a negative effect on calcium 
homeostasis by decreasing absorption of calcium from 
the intestine and increasing calcium loss in the urine, as 
a result of defective vitamin D metabolism. This leads to 
secondary hyperparathyroidism, which results in increased 
bone resorption.15,16 Moreover, GCs affect bone metabolism 
indirectly by reducing levels of sex hormones as a result of 
suppressed pituitary gonadotrophin secretion.16
Treatment of glucocorticoid-induced 
osteoporosis and bisphosphonates
As GIO is an important problem due to the increased risk of 
fracture, preventive measures are suggested in order to stabi-
lize or increase the BMD in such patients, and consequently 
reduce the risk of fracture. It has been demonstrated that regu-
lar BMD assessment, and management of osteoporosis is sub-
optimal in patients using long-term GCs, despite the fact that 
screening and treatment rates have increased in recent years.19 
In an attempt to increase the rates of screening and treatment 
of osteoporosis in long-term GC users, Curtis et al employed 
an online continuing medical education program for physi-
cians who prescribed long-term GC therapy.20 Although the 
final results of this study revealed that the education provided 
did not yield any advantage when compared to the control 
group, a greater amount of education may be beneficial and 
the mode of education may affect the outcome.
Calcium and vitamin D supplementation, increasing BMD, 
and preventing high cortisol levels, are the main strategies in 
treating GIO. Moreover, numerous clinical trials have now 
demonstrated that bisphosphonates are highly effective at 
limiting bone loss in patients with GIO.21 Furthermore, in 
GC-treated patients at high risk of fracture, bisphosphonate 
therapy has proved to be cost-effective.22 Thus, nowadays 
bisphosphonates are considered to be the gold standard for the 
prevention and treatment of GIO, along with sufficient intakes 
of calcium and vitamin D as they increase BMD, and reduce 
vertebral fracture risk in patients beginning or continuing GC 
treatment.23–28 The nitrogen-containing bisphosphonates act by 
inhibiting farnesyl diphosphate (FPP) synthase, a key enzyme 
of the mevalonate pathway, which is critical to the production 
of cholesterol, other sterols, and isoprenoid lipids. The inhibi-
tion of osteoclasts by the nitrogen-containing bisphosphonates 
is very likely mediated by their action on the FPP synthase, 
which leads to protracted apoptosis of these giant cells.29,30
Although daily oral bisphosphonate therapy with 
alendronate or risedronate is effective for treatment of 
GIO, compliance and adherence with daily and weekly 
therapy has been shown to be suboptimal.31–35 This finding 
is important, as an association between poor adherence and 
increased fracture risk has been demonstrated in women 
with postmenopausal osteoporosis who were treated with 
oral bisphosphonate.36 Therefore, studies were conducted 
in order to search for an alternative treatment regime which 
would increase the compliance and adherence of patients 
with GIO.37
Zoledronic acid in the treatment  
of glucocorticoid-induced osteoporosis
Like other bisphosphonates, zoledronic acid binds to the cal-
cium phosphate bone mineral hydroxyapatite, predominantly 
localizing at regions of high bone turnover.38,39 Additionally, 
the affinity of zoledronic acid for hydroxyapatite was shown 
to be higher than that of other bisphosphonates in an in vitro 
study.38 In osteoporosis, zoledronic acid inhibits osteoclast-
mediated resorption, therefore reducing bone turnover.
Zoledronic acid, which is available as an intravenous 
formulation, is approved for the treatment of osteoporosis 
in postmenopausal women and, more recently, in men at 
increased risk of fracture, and in patients in Europe with 
a recent low-trauma hip fracture.40 Intravenous zoledronic 
acid 5 mg, administered via infusion, is the first once-yearly 
treatment approved for these indications.41–44
The efficacy of zoledronic acid for preventing and treating 
GIO was studied by HORIZON (Health Outcomes and 
Reduced Incidence with Zoledronic Acid Once) investigators 
in a large international study, where patients were randomized 
to receive either intravenous 5 mg zoledronic acid or oral 5 mg 
risedronate.37 This study demonstrated that one 5 mg infusion 
of zoledronic acid annually increases bone mineral density of 
the lumbar spine and femoral neck, trochanter, and total hip 
more than the oral 5 mg risedronate daily, in patients who had 
recently started GCs (prevention group n:288) and in those who 
had been already taking them (treatment group n:545).37 The 
patients were followed for 12 months and BMD was measured 
at 6th and 12th months. The primary endpoint of the study was 
the percentage change from baseline in BMD, while changes 
in bone turnover biomarker concentrations were measured as 
secondary end-points. Evaluation of this study indicated that 
the increase in BMD at 6 months was significantly higher with 
zoledronic acid than it was with risedronate (Figure 1). It has Therapeutics and Clinical Risk Management 2010:6 221
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also been shown that inhibition of the bone turnover markers 
was faster and more substantial in patients receiving zoledronic 
acid. Unfortunately, this study was not able to detect differences 
in fracture risk.37 However, various studies have demonstrated 
that once-yearly administration of zoledronic acid 5 mg is 
effective in preventing fractures.45–47 Bearing this in mind, we 
may speculate that annual administration of 5 mg zoledronic 
acid will be efficacious in preventing bone fractures. However 
this speculation requires further studies to verify it.
Severe adverse effects associated with the use of intravenous 
bisphosphonates are uncommon, however approximately 
10% to 30% of patients receiving their first nitrogen-contain-
ing bisphosphonate infusion will experience an acute phase 
reaction within the first 3 days of treatment. This is most 
commonly characterized by transient pyrexia with associated 
myalgias, arthralgias, headaches, and influenza-like symp-
toms.37 This acute phase response is believed to be the result 
of proinflammatory cytokine production by peripheral blood 
T cells.48 The reactions are typically self-limited and resolve 
completely within 24 to 48 hours. In addition to the adminis-
tration of adequate fluid, NSAIDs or acetaminophen may be 
useful supportive treatments. The frequency of pyrexia within 
the first days of treatment was 15% in a study where no co-drug 
was used during the administration of zoledronic acid, however 
in a study where NSAIDs or paracetamol was administered 
with zoledronic acid the rate was 8.7% (Figure 1).37,45 Fortu-
nately, the frequency of these reactions is rare in subsequent 
  infusions of nitrogen-containing biphosphonates.37,49
Ocular complications, nephrotoxicity, and/or electrolyte 
abnormalities such as hypocalcemia, hypophosphatemia, 
and hypomagnesemia are also reported.31 The most frequent 
observed ocular complication is nonspecific conjunctivitis, 
which is usually self-limited.50 On the other hand uveitis can 
also be seen after the administration of zoledronic acid and 
this requires medical treatment.51 The physician administer-
ing intravenous bisphosphonates should be alert for such 
situations where patients present with ocular pain, itching, 
or decrease in vision, and in such cases they should promptly 
direct the patient to be examined by an opthalmologist.50
Previous studies have proved that the effect of risdero-
nates on renal functions is comparable with placebo even 
in patients with impaired renal functions.52 It is well known 
that all intravenous bisphophonates have the potential to 
affect renal functions, especially in patients whose renal 
function is compromised.53 However the findings of the 
HORIZON study did not demonstrate a higher rate of renal 
impairment in patients receiving zoledronic acid treatment 
than in patients in the risedronate arm.37 When we take the 
  previously-mentioned studies’ results into consideration it 
may be further speculated that zoledronic acid may be com-
parable with placebo with respect to renal complications.
Electrolyte abnormalities can also be a problem in 
zoledronic acid treatment. In a multicenter review hypo-
calcemia was reported in 35% of patients after zoledronic 
acid infusion whereas symptomatic hypocalcemia requiring 
treatment was observed in 8% of patients despite prophylactic 
measures.54
Bisphosphonates have been linked to osteonecrosis of the 
jaw which can be prevented with pretherapy dental care.55 It 
has been shown that prolongation of bisphosphonate treat-
ment increases the frequency of osteonecrosis of the jaw.56 
The management of this situation is a matter for debate and 
depends on the stage at which it is diagnosed.
In the HORIZON-PFT (Health Outcomes and Reduced 
Incidence with Zoledronic Acid Once Pivotal Fracture 
Trial), where patients were treated annually with intrave-
nous zoledronic acid, a statistically-significant increase in 
the incidence of serious atrial fibrillation (defined as events 
resulting in hospitalization, or disability, or judged to be 
life-threatening) was noted.42 The etiology of this electro-
physiologic abnormality is not clarified yet. Unfortunately, 
we have limited data regarding other bisphosphonate 
preparations which may have the potential to produce similar 
rates of atrial fibrillation. One large population-based case-
control study suggested a correlation between alendronate 
administration and a slightly-increased incidence of atrial 
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Figure 1 Percentage changes in BMD of lumbar spine in GIO patients treated with 
either daily risedronate or annual zoledronic acid (HORIZON).37
Abbreviations: BMD, bone mineral density; GIO, glucocorticoid-induced osteo-
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fibrillation, whereas another population-based case-control 
study showed no evidence of an increased risk of atrial fibril-
lation or flutter with alendronate use.57,58 On the other hand, 
no increase was detected in the rate of atrial fibrillation seen 
in patients received IV zoledronic acid after a hip fracture 
(the HORIZON Recurrent Fracture Trial).45,59 Apparently, 
more studies examining the potential relationship between 
bisphosphonate use and atrial fibrillation are required.
Conclusion
Since GCs are essential in treating many disorders, physi-
cians should consider their negative effects on skeletal health, 
and they must be aware of GIO prior to administering these 
drugs. As bisphosphonates reduce bone resorption through 
their actions on osteoclasts, they play an important role in 
management of GIO. However awareness rates are much 
below those expected. Future studies focusing on improv-
ing the understanding of GIO and its management should be 
conducted, as it may be beneficial to increase the awareness 
of physicians about GIO and its treatment options through 
rigorous education programs.
Zoledronic acid, which is given by intravenous infusion, 
has a potential advantage of increasing the compliance and 
adherence of patients when it is given 5 mg, once a year. 
Zoledronic acid is effective in preventing and treating GIO, 
with a overall high safety and tolerability rate, and a low 
rate of serious adverse events. Future studies concentrating 
on the long-term effects and cost-effectiveness would be 
  beneficial. In addition, research focusing on new targets such 
as anabolic drugs which stimulate bone formation by acting 
on osteoblasts and osteocytes could lead to a more compel-
ling rationale for use than bisphosphonates.
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